-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
The results of KN026 second-line treatment of HER2-expressing gastric cancer or gastroesophageal junction cancer were published in the internationally renowned journal EJC
Time of Update: 2023-01-01
About KN026 KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights, which can bind two non-overlapping epitopes of HER2 at the same time, resulting in HER2 signal blockade, which is better than the combination of trastuzumab and pertuzumab, such as showing higher affinity, and has a potent tumor suppressor effect in HER2-positive tumor cell lines.
-
Bose has achieved results in promoting drug reform, and the people's sense of gain has gradually increased
Time of Update: 2022-12-30
Since participating in the procurement of pharmaceutical groups, the city has completed the signing of drug contracts and procurement amounts of 650 million yuan, an average reduction of 56%, saving procurement costs of 828 million yuan, and reducing the economic burden of patients by 328 million yuan according to the reimbursement ratio of the medical insurance fund policy.
-
The localization strategy of domestic pharmaceutical enterprises has been upgraded, and the transformation to innovation has become a trend
Time of Update: 2022-12-29
Carestream Health is trying to broaden its product pipeline, and in the future, the company will continue to tailor products for all levels of the domestic market, and provide broader solutions, so as to achieve full coverage of high-end, high-end and low-end products in the Chinese market, so that innovation can benefit more people.
-
Clariant launches carbon footprint calculation tool
Time of Update: 2022-11-25
”On November 8, Clariant announced the launch of CliMate, a product carbon footprint (PCF) calculation tool.
”On November 8, Clariant announced the launch of CliMate, a product carbon footprint (PCF) calculation tool.
”On November 8, Clariant announced the launch of CliMate, a product carbon footprint (PCF) calculation tool.
-
The considerations behind the introduction of The New Medical Insurance Policy in Beijing? Interview with Zheng Jie, head of the Drg technical guidance group of the National Medical Insurance
Time of Update: 2022-09-14
"The main role of DRG is to standardize medical behavior, and supporting medical innovation is the 'icing on the cake', but it cannot be erased from its most basic 'charcoal in the snow' function. "
-
This article will take you to understand the market status, competition pattern and development trend of China's medical device industry in 2021
Time of Update: 2022-08-28
In these major medical device production provinces, industrial agglomeration advantages have gradually formed From the perspective of regional distribution, as of the end of 2020, there were 4,553 medical device manufacturers in Guangdong Province, occupying the highest market share (17.
-
The large-scale RCT study of QFR technology by Professor Tu Shengxian's group from the School of Biomedical Engineering was selected into the "China's 2021 Important Medical Progress" by the Chinese
Time of Update: 2022-05-18
The post-marketing large-scale randomized controlled clinical trial FAVOR III China of computational physiology QFR technology developed by Academician Chen Yazhu's team of Shanghai Jiaotong University and Professor Tu Shengxian's research group "non-invasive computational physiology technology to guide coronary intervention to improve clinical prognosis" was successfully selected in the field of clinical medicine " Important medical progress in China in 2021 .
-
National Medical Insurance Administration: A total of 20 billion yuan of special funds for the treatment of new coronary pneumonia has been allocated
Time of Update: 2022-05-14
The reporter learned from the National Medical Insurance Bureau that since the outbreak of the new crown pneumonia, the national medical insurance system has resolutely implemented the decisions and d
-
MedAlliance announces completion of Japanese research recruitment
Time of Update: 2021-10-23
Geneva, September 24, 2021/PRNewswire/ - MedAlliance and its Japanese partner MDK Medical have completed the clinical trial of its new sirolimus drug-eluting balloon (DEB) SELUTION SLR™ for the treatment of peripheral arterial disease (PAD) Research recruitment .
-
Wei 11 gas storage drilling "factory" construction mode is put into operation
Time of Update: 2021-10-12
Recently, more than 190 people from 4 teams including the 50608 Drilling Team of the Second Drilling Company of Zhongyuan Petroleum Engineering Company entered the life centralized management and logistics support service area of Wei 11 gas storage, marking the beginning of the operation of the "factory" drilling construction mode.
-
North China Oil and Gas Ground Rapid and Optimal Deployment and Construction to Accelerate Gas Field Capacity Release
Time of Update: 2021-10-11
With the continuous production of Dongsheng Gas Field, the ground gathering and transportation technology is also being adapted and improved in real time based on the development and operation of the gas field .
-
"Shenhai No. 1" large gas field is fully put into production, and the high-quality development of offshore oil and gas adds vitality
Time of Update: 2021-09-10
After the gas field is put into production, it will provide a stable supply of over 3 billion cubic meters of deep-sea natural gas to Guangdong, Hong Kong, Macau, Greater Bay Area and Hainan each year, which is of great significance to safeguarding national energy security, driving the economic development of surrounding regions, and transforming and upgrading the energy structure .
-
Carbon neutral LNG is gaining momentum
Time of Update: 2021-08-06
" Gazprom’s vice chairman and export supervisor Bumistrova said that the delivery of carbon-neutral LNG shows that the natural gas industry can also help achieve global climate goals .
